Peter Hartman

2.4k total citations · 1 hit paper
39 papers, 2.0k citations indexed

About

Peter Hartman is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Peter Hartman has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 7 papers in Infectious Diseases and 7 papers in Oncology. Recurrent topics in Peter Hartman's work include Plant biochemistry and biosynthesis (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Cholesterol and Lipid Metabolism (5 papers). Peter Hartman is often cited by papers focused on Plant biochemistry and biosynthesis (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Cholesterol and Lipid Metabolism (5 papers). Peter Hartman collaborates with scholars based in Switzerland, United Kingdom and Canada. Peter Hartman's co-authors include Francesc Avilés, James M. Allan, Colyn Crane‐Robinson, E. Morton Bradbury, George E. Chapman, Tom Moss, A. C. Oehlschlager, Rudolf Then, Hans H. Locher and Yi Zheng and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Molecular Biology.

In The Last Decade

Peter Hartman

38 papers receiving 1.9k citations

Hit Papers

The structure of histone H1 and its location in chromatin 1980 2026 1995 2010 1980 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The structure of histone H1 and its location in chromatin
    1980 606 citations Peter Hartman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Hartman Switzerland 23 1.4k 230 210 178 169 39 2.0k
Ellen W. Moomaw United States 13 1.1k 0.8× 137 0.6× 256 1.2× 242 1.4× 268 1.6× 19 1.8k
Andrew Binkowski United States 4 1.2k 0.9× 117 0.5× 174 0.8× 126 0.7× 126 0.7× 4 1.8k
David T. Barkan United States 12 1.4k 1.0× 238 1.0× 139 0.7× 206 1.2× 152 0.9× 16 1.9k
Nina M. Haste United States 23 1.9k 1.4× 204 0.9× 260 1.2× 229 1.3× 175 1.0× 29 2.8k
Alexander E. Aleshin United States 28 1.3k 0.9× 280 1.2× 236 1.1× 210 1.2× 166 1.0× 53 2.5k
Rao Sethumadhavan India 23 1.3k 0.9× 136 0.6× 111 0.5× 185 1.0× 85 0.5× 88 1.8k
Wolfgang Knecht Sweden 28 1.5k 1.1× 111 0.5× 348 1.7× 122 0.7× 204 1.2× 83 2.1k
H.T. Wright United States 26 2.0k 1.4× 196 0.9× 164 0.8× 203 1.1× 91 0.5× 61 3.0k
Joseph Dundas United States 4 1.1k 0.8× 136 0.6× 131 0.6× 126 0.7× 72 0.4× 6 1.6k
E. Malito Italy 23 1.2k 0.9× 162 0.7× 279 1.3× 176 1.0× 337 2.0× 42 2.1k

Countries citing papers authored by Peter Hartman

Since Specialization
Citations

This map shows the geographic impact of Peter Hartman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hartman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hartman more than expected).

Fields of papers citing papers by Peter Hartman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hartman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hartman. The network helps show where Peter Hartman may publish in the future.

Co-authorship network of co-authors of Peter Hartman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hartman. A scholar is included among the top collaborators of Peter Hartman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hartman. Peter Hartman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hartman, Peter, Vincenzo di Bari, Jiraphong Suksiriworapong, et al.. (2025). Enzymatic Synthesis of Functional PEGylated Adipate Copolymers. ChemPlusChem. 90(5). e202400668–e202400668.
2.
Mohr, Peter, Bernd Kuhn, Hans Peter Maerki, et al.. (2012). Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors. ChemMedChem. 7(6). 1101–1111. 37 indexed citations
3.
Gardès, Christophe, Denise Blum, Konrad Bleicher, et al.. (2011). Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor. Journal of Lipid Research. 52(6). 1188–1199. 14 indexed citations
4.
Richter, Hans, G. Martin Benson, Konrad Bleicher, et al.. (2011). Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorganic & Medicinal Chemistry Letters. 21(4). 1134–1140. 67 indexed citations
5.
Richter, Hans, G. Martin Benson, Denise Blum, et al.. (2010). Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorganic & Medicinal Chemistry Letters. 21(1). 191–194. 49 indexed citations
6.
Bot, Ilze, Martine Bot, Sandra H. van Heiningen, et al.. (2010). Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE−/− mice. Cardiovascular Research. 89(1). 244–252. 56 indexed citations
7.
Panday, Narendra, Jörg Benz, Denise Blum‐Kaelin, et al.. (2006). Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β. Bioorganic & Medicinal Chemistry Letters. 16(19). 5231–5237. 10 indexed citations
8.
Dale, Glenn E., Clemens Broger, Peter Hartman, et al.. (1997). A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance 1 1 Edited by T.Richmond. Journal of Molecular Biology. 266(1). 23–30. 130 indexed citations
9.
Stach, Dirk, Yi Zheng, Alice L. Pérez, et al.. (1997). Synthesis and Inhibition Studies of Sulfur-Substituted Squalene Oxide Analogues as Mechanism-Based Inhibitors of 2,3-Oxidosqualene−Lanosterol Cyclase. Journal of Medicinal Chemistry. 40(2). 201–209. 28 indexed citations
10.
Mehlhorn, H., et al.. (1995). A pilot study on the efficacy of epiroprim against developmental stages ofToxoplasma gondii andPneumocystis carinii in animal models. Parasitology Research. 81(4). 296–301. 7 indexed citations
11.
Henein, Naeim A., et al.. (1995). In-Situ Phase-Shift Measurement of the Time-Resolved UBHC Emissions. SAE technical papers on CD-ROM/SAE technical paper series. 1. 3 indexed citations
12.
Then, Rudolf, et al.. (1994). Epiroprim < Rec INN >. Drugs of the Future. 19(5). 446–446. 4 indexed citations
13.
Morand, O., Johannes D. Aebi, Peter Hartman, et al.. (1994). Potent inhibitors of mammalian 2,3-oxidosqualene lanosterol cyclase are orally active cholesterol lowering agents. Atherosclerosis. 109(1-2). 321–321. 3 indexed citations
14.
Then, Rudolf, Peter Hartman, I. Kompiš, & Daniel V. Santi. (1993). Selective Inhibition of Dihydrofolate Reductase from Problem Human Pathogens. Advances in experimental medicine and biology. 533–536. 10 indexed citations
15.
Hartman, Peter. (1993). Molecular Aspects and Mechanism of Action of Dihydrofolate Reductase Inhibitors. Journal of Chemotherapy. 5(6). 369–376. 36 indexed citations
16.
Dodd, Dharmpal S., et al.. (1992). Synthesis of inhibitors of 2,3-oxidosqualene-lanosterol cyclase. 2. Cyclocondensation of .gamma.,.delta.-unsaturated-.beta.-keto esters with imines. The Journal of Organic Chemistry. 57(26). 7226–7234. 39 indexed citations
17.
Polak, Annemarie & Peter Hartman. (1991). Antifungal chemotherapy — Are we winning?. Birkhäuser Basel eBooks. 37. 181–269. 25 indexed citations
18.
19.
Cary, Peter D., K.V. Shooter, Graham H. Goodwin, et al.. (1979). Does high-mobility-group non-histone protein HMG 1 interact specifically with histone H1 subfractions?. Biochemical Journal. 183(3). 657–662. 23 indexed citations
20.
Hartman, Peter, George E. Chapman, Tom Moss, & E. Morton Bradbury. (1977). Studies on the Role and Mode of Operation of the Very‐Lysine‐Rich Histone H1 in Eukaryote Chromatin. European Journal of Biochemistry. 77(1). 45–51. 270 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen W. Moomaw Breakdown of academic impact, for papers by Andrew Binkowski Breakdown of academic impact, for papers by David T. Barkan Breakdown of academic impact, for papers by Nina M. Haste Breakdown of academic impact, for papers by Alexander E. Aleshin Breakdown of academic impact, for papers by Rao Sethumadhavan Breakdown of academic impact, for papers by Wolfgang Knecht Breakdown of academic impact, for papers by H.T. Wright Breakdown of academic impact, for papers by Joseph Dundas Breakdown of academic impact, for papers by E. Malito
Rankless by CCL
2026